Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q1 2024 · 10-Q
Revenue$55.00K$55.00K−14.1% vs Q1 2023 Net Income-$2.27M-$2.27MN/M vs Q1 2023 EPS, diluted—
Operating Income-$2,275,000N/M Operating Cash Flow-$1,530,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,530,000N/M Margins · derivedOperating margin-4136.4%+1348.0 pt vs Q1 2023
Net margin-4121.8%+1348.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end